InsidersTradesSigma
Follow the ATAI Life Sciences N.V. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ATAI Life Sciences N.V. has logged 44 insider filings. Market capitalisation: €2.6bn. The latest transaction was filed on 2 October 2025 (C). Among the most active insiders: Apeiron Investment Group Ltd.. Every trade is accessible without an account.
44
Insider Decl.
n/a
Thresholds
€62m
24 ops.
Buy Volume
€708,418
9 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ATAI Life Sciences N.V. Buy (bullish), based on 8 analysts. Average price target: US$11.78.
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 October 2025
Declarations44 total
2,367,200 sharesCommon SharesSEC:0001193125-25-228361:0
8,675,799 shares@ US$2.1931.2% of flowCommon SharesSEC:0000950170-25-109858:0
Canonical exit: 12 Nov 2025 (T+90)
1,800,000 shares@ US$1.405.2% of flowCommon SharesSEC:0000950170-25-043942:0
Canonical exit: 22 Jun 2025 (T+90)
13,161 shares@ US$1.35100.0% of flowCommon SharesSEC:0001140361-25-010112:0
33,545 shares@ US$1.3547.0% of flowCommon SharesSEC:0001140361-25-010113:0
48,563 shares@ US$1.3549.5% of flowCommon SharesSEC:0001140361-25-010116:0
75,418 shares@ US$1.3532.6% of flowCommon SharesSEC:0001140361-25-010114:0
11,563 shares@ US$1.35100.0% of flowCommon SharesSEC:0001140361-25-010115:0
100,000 sharesCommon SharesSEC:0001140361-25-009511:0
100,000 sharesCommon SharesSEC:0001140361-25-009510:0
20,000 sharesCommon SharesSEC:0001140361-25-009514:0
32,500 sharesCommon SharesSEC:0001140361-25-009513:0
175,000 sharesCommon SharesSEC:0001140361-25-009512:0
10,835,718 shares@ US$2.1048.5% of flowCommon SharesSEC:0000950170-25-023436:0
Canonical exit: 15 May 2025 (T+90)
151,303 shares@ US$1.9253.8% of flowCommon SharesSEC:0001140361-24-026915:0
35,801 shares@ US$1.8550.5% of flowCommon SharesSEC:0001140361-24-018027:0
27,410 shares@ US$1.8553.0% of flowCommon SharesSEC:0001140361-24-018029:0
61,640 shares@ US$1.8536.8% of flowCommon SharesSEC:0001140361-24-018028:0
100,000 sharesCommon SharesSEC:0001140361-24-013628:0
350,000 sharesCommon SharesSEC:0001140361-24-013625:0
100,000 sharesCommon SharesSEC:0001140361-24-013627:0
175,000 sharesCommon SharesSEC:0001140361-24-013626:0
20,000 shares@ US$1.1564.3% of flowCommon SharesSEC:0001140361-23-053957:0
Canonical exit: 14 Feb 2024 (T+90)
40,000 shares@ US$1.449210.9% of flowCommon SharesSEC:0000950170-23-048195:0
Canonical exit: 12 Dec 2023 (T+90)
70,000 shares@ US$1.479419.2% of flowCommon SharesSEC:0000899243-23-010034:0
Canonical exit: 27 Jun 2023 (T+90)
25 of 44 declarations
关于 ATAI Life Sciences N.V.
ATAI Life Sciences N.V.（股票代码：ATAI）是一家在美国上市的生物制药公司，在纳斯达克交易，专注于开发精神健康疾病的创新疗法。该公司成立于 2018 年，旨在应对精神病学领域持续未满足的需求，因为许多患有抑郁症、焦虑症、成瘾症和其他难以治疗的疾病的患者仍未能从现有疗法中充分受益。ATAI 以平台式“公司建设者”的模式运营，结合资本配置、科学专业知识、监管知识和运营支持，孵化并推进差异化的治疗项目，包括基于迷幻剂和其他具有潜在临床价值的新型化合物。该公司的根基在柏林，并通过与纽约相关的办事处和运营保持国际足迹，反映出旨在解决全球精神健康市场的跨大西洋结构。其管线以临床阶段资产为中心，例如 VLS-01（一种用于治疗抵抗性抑郁症的 DMT 口腔膜剂）；BPL-003（一项用于治疗抵抗性抑郁症的鼻内甲呋丁苯甲酸酯项目，通过对 Beckley Psytech 的战略投资推进）；以及 EMP-01（一项针对社交焦虑症的口服 R-MDMA 项目）。从投资角度来看，这种多元化的管线很重要，因为它减少了对单一资产的依赖，同时使公司能够接触到下一代精神病学疗法更广泛的重估潜力。在竞争方面，ATAI 参与了一个要求极高的领域，成功取决于临床执行、耐受性、监管进展、知识产权实力和资本获取。最近的新闻流包括 VLS-01 持续推进到 1b 期、BPL-003 的持续开发工作以及 2025 年的财务更新，这些都强化了 ATAI 作为一家尚未实现产品商业化的临床阶段公司的地位。对于欧洲投资者而言，ATAI 最好被视为与一个非常庞大且结构性服务不足的潜在市场相关的、高风险、高回报的生物技术投资。其对精神健康的战略重点仍然引人注目，但投资案例仍取决于临床数据公布、监管里程碑和融资纪律。
